ALL-BFM Registry

The primary objective of the ALL-BFM registry is to collect population-based medical data from children and adolescents with ALL, regardless of participation in a clinical trial.
The acquisition and regular analysis of the data is intended to contribute to ensuring the quality of the structure, process and results regarding diagnosis and treatment of children with ALL in accordance with the Paediatric Oncology Directive (KiOn-RL). This also includes the possibility of analyses for historical comparison with previous study populations or with ALL cohorts of other study groups.

Objectives of the ALL-BFM Registry:

• Structured acquisition and analysis of population-based data of patients under 18 years of age with ALL to map the actual health care situation in Germany as well as to evaluate and ensure the quality of the structure, process and outcome of the care of children and
• Provision of data for the planning of (clinical) studies and scientific research projects
• Use of data for central screening for inclusion and exclusion criteria for clinical trials conducted by or associated with the ALL-BFM study group
• Provision of data for research on ALL

• First diagnosis of acute lymphoblastic leukaemia or mixed phenotype acute leukaemia (MPAL) (biphenotypic or bilinear) or acute undifferentiated leukaemia,
• age under 18 years on the day of initial diagnosis,
• treatment of the patient in one of the centres participating in the registry,
• written consent of the patient or guardian to be enrolled in the ALL-BFM registry

• Diagnosis before 01/05/2024